#ESCCongress | Estudo randomizado: finerenona reduziu os eventos cardiovasculares em pacientes com doença renal e diabetes tipo 2 (12,4% vs. 14,2% durante um seguimento médio de 3,4 anos), mas o risco de hiperpotassemia foi aumentado (10,8% vs. 5,3%).

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes – New England Journal of Medicine

Comunicado de imprensa: Finerenone benefits patients with diabetes across spectrum of kidney disease – European Society of Cardiology

Comentários:

Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease – FIGARO-DKD – American College of Cardiology

FIGARO-DKD and FIDELITY Findings Show Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease, Diabetes – American College of Cardiology

Conteúdo relacionado: [Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes

Comentário no Twitter

FIGARO-DKD: Among patients with stage 1 to 4 CKD and T2 diabetes, finerenone improved CV outcomes as compared with placebo. #ESCCongress https://t.co/mcfmvftBvy pic.twitter.com/qizit80NBa

— NEJM (@NEJM) August 28, 2021